{'fraction_non_alphanumeric': 0.03282828282828283, 'fraction_numerical': 0.021043771043771045, 'mean_word_length': 5.291005291005291, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Over‐expression of bcl‐xL gene in human gastric adenomas and carcinomas

The present study was designed to clarify whether bel‐xL is involved in the development of carcinoma in the stomach. Levels of bel‐xL and bc1‐2 mRNA were determined by a reverse‐transcription/polymerase‐chain reaction in endoscopic gastric biopsy specimens from 10 control subjects, 11 patients with adenomas and 14 patients with carcinomas. In 6 of 11 adenomas, 5 of 8 early carcinomas and 3 of 6 advanced carcinomas, the bel‐xL gene was over‐expressed. In carcinomas, overexpression of the bel‐xL gene was observed in 6 of 9 intestinaltype carcinomas and 2 of 5 diffuse‐type carcinomas. No correlation was observed between bel‐xL and bc1‐2 gene expression. In cases in which the bel‐xL gene was over‐expressed, an apparent increase in the protein level of Bcl‐xL was observed by immunoblot analysis and intense Bcl‐x immunoreactivity was detected immunohistochemically within the tumor cells. In conclusion, we showed that bel‐xL is over‐expressed in gastric carcinomas at both the RNA and protein levels, suggesting that overexpression of bel‐xL may play a role in gastric carcinogenesis. © 1996 Wiley‐Liss, Inc.